

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Sharad Magar	Title:	PIPERAZINE DERIVATIVES AND METHODS OF USE
App. No.:	10/528,437	Art Unit:	4121
Conf. No.:	4300	Examiner:	Pihonak, Sarah Maureen
Filing Date:	April 10, 2006		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97(d) and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Form PTO/SB/08A&B. This Information Disclosure Statement is submitted after the period specified in 37 C.F.R. § 1.97(c) and on or before payment of the issue fee and is therefore accompanied by the statement specified in 37 C.F.R. § 1.97(e)(1) and the fee of \$180 as set forth in 37 C.F.R. § 1.17(p). It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO/SB/08A&B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement does not include a copy of cited U.S. patents or publications pursuant to 37 C.F.R. 1.98(a)(2).

In accordance with 37 C.F.R. § 1.97(e)(1), Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

No other fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees be deemed necessary, and proper, the Commissioner is hereby authorized to deduct any such fees from Deposit Account 08-3038.

Respectfully submitted,

HOWREY LLP

Dated: March 11, 2010

By: /David W. Clough/
David W. Clough, Ph.D.
Registration No.: 36,107
Customer No.: 22930
Telephone No.: (312) 595-1408

Enclosure:
Form PTO/SB/08A&B

HOWREY LLP
ATTN: Docketing Department
2941 Fairview Park Drive, Suite 200
Falls Church, VA 22042-2924
Facsimile No.: (703) 336-6950